Clinical Focus

Previous Articles     Next Articles

Therapeutic advancements of biologic agents in rheumatic disease

  

  1. Department of Immunology and Rheumatology, the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China
  • Online:2016-05-05 Published:2016-05-04
  • Contact: Corresponding author: Jin Hongtao,Email: 15803210963@163.com

Abstract:

Biological agent is a recombinant product that is selectively targeted to the immune response or to the inflammatory process, or to the target of a monoclonal antibody or a natural inhibitor of the target. The biologic drugs have wide variety, the major targets of most biologic therapies are cytokines, B cells and costimulation molecules, including tumor necrosis factor (TNF) inhibitors,antiinterleukin6 receptor monoclonal antibody, antiCD20 antibodies rutximab and other drugs. They are prescribed for the treatment of rheumatoid arthritis, ankylosing  spondylitis,systemic lupus erythematosus and other autoimmune disease.The use of biological agents should pay attention to safety. It is necessary to screen tuberculosis and exclude active infections and cancer before the use of biologic agents. Reduction dose or stopping biological drug need to be discussed.

Key words: biological products, tumor necrosis factors, arthritis, rheumatoid; , spondylitis